These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26569379)

  • 1. The ABCs of the US Broad Spectrum Antimicrobials Program: Antibiotics, Biosecurity, and Congress.
    Billington JK
    Health Secur; 2015; 13(6):349-54. PubMed ID: 26569379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic resistance.
    Rambhia KJ; Gronvall GK
    Biosecur Bioterror; 2009 Dec; 7(4):371-7. PubMed ID: 20028245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
    Spellberg B; Guidos R; Gilbert D; Bradley J; Boucher HW; Scheld WM; Bartlett JG; Edwards J;
    Clin Infect Dis; 2008 Jan; 46(2):155-64. PubMed ID: 18171244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global need for effective antibiotics: challenges and recent advances.
    Högberg LD; Heddini A; Cars O
    Trends Pharmacol Sci; 2010 Nov; 31(11):509-15. PubMed ID: 20843562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.
    Aiello AE; King NB; Foxman B
    Am J Public Health; 2006 Nov; 96(11):1910-4. PubMed ID: 17018817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The food safety perspective of antibiotic resistance.
    McDermott PF; Zhao S; Wagner DD; Simjee S; Walker RD; White DG
    Anim Biotechnol; 2002 May; 13(1):71-84. PubMed ID: 12212946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Access to Effective Antibiotics is Essential for Tackling Antibiotic Resistance.
    Daulaire N; Bang A; Tomson G; Kalyango JN; Cars O
    J Law Med Ethics; 2015; 43 Suppl 3():17-21. PubMed ID: 26243238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Product Development Partnership Model for Antibiotic Resistance.
    Billington JK
    Am J Law Med; 2016 May; 42(2-3):487-523. PubMed ID: 29086636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination drugs, an emerging option for antibacterial therapy.
    Cottarel G; Wierzbowski J
    Trends Biotechnol; 2007 Dec; 25(12):547-55. PubMed ID: 17997179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical countermeasures for national security: a new government role in the pharmaceuticalization of society.
    Elbe S; Roemer-Mahler A; Long C
    Soc Sci Med; 2015 Apr; 131():263-71. PubMed ID: 24815579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empty antibiotic pipeline critically endangers public: IDSA report.
    James JS
    AIDS Treat News; 2004 Aug; (404):7. PubMed ID: 15484367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who will develop new antibacterial agents?
    Cole ST
    Philos Trans R Soc Lond B Biol Sci; 2014; 369(1645):20130430. PubMed ID: 24821916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.